Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Depression

Therapeutic area intelligence for Depression with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
3
Catalysts
0
Companies
1

Companies

Janssen Pharmaceuticals →

Assets

Alembic →
Moodivate →
SPRAVATO →

Recent signals(3)

ClinicalJune 11, 2026

Pilot Trial of Digitally Enhanced Stepped-Care for Depression in Primary Care Initiated

A pilot trial is evaluating a digitally enhanced stepped-care approach for treating depression in primary care settings.

RegulatoryJune 10, 2026

FDA Accepts Supplement for SPRAVATO (Esketamine Hydrochloride)

The FDA has accepted a supplemental application for SPRAVATO, indicating ongoing development and potential label expansion.

RegulatoryJune 7, 2026

Alembic's Duloxetine Hydrochloride Supplement Receives AP Status from FDA

Alembic's application for Duloxetine Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.